Key Points
- PTC director Emma Reeve sold 733 shares on Dec. 3 at $78.62 (≈$57,628), leaving her with 6,666 shares (a 9.91% ownership drop), and those trades are part of a series of insider sales since Sept. 11 totaling roughly $5.1 million.
- PTCT shares opened around $77.25 with a market cap of $6.2B and a 52‑week range of $35.95–$87.50; the company posted an earnings beat (EPS $0.20 vs. -$1.19 est.) but the consensus analyst stance is a "Hold" with an average target of $76.
PTC Therapeutics, Inc. (NASDAQ:PTCT - Get Free Report) Director Emma Reeve sold 733 shares of the company's stock in a transaction dated Wednesday, December 3rd. The shares were sold at an average price of $78.62, for a total value of $57,628.46. Following the sale, the director owned 6,666 shares in the company, valued at approximately $524,080.92. This represents a 9.91% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.
Emma Reeve also recently made the following trade(s):
- On Friday, November 21st, Emma Reeve sold 10,000 shares of PTC Therapeutics stock. The shares were sold at an average price of $79.50, for a total transaction of $795,000.00.
- On Wednesday, November 12th, Emma Reeve sold 7,333 shares of PTC Therapeutics stock. The stock was sold at an average price of $74.50, for a total transaction of $546,308.50.
- On Thursday, October 30th, Emma Reeve sold 15,666 shares of PTC Therapeutics stock. The stock was sold at an average price of $69.50, for a total transaction of $1,088,787.00.
- On Friday, October 3rd, Emma Reeve sold 25,562 shares of PTC Therapeutics stock. The shares were sold at an average price of $65.96, for a total transaction of $1,686,069.52.
- On Thursday, September 11th, Emma Reeve sold 15,705 shares of PTC Therapeutics stock. The stock was sold at an average price of $59.50, for a total transaction of $934,447.50.
PTC Therapeutics Stock Performance
Shares of PTCT stock opened at $77.25 on Friday. The company has a market capitalization of $6.20 billion, a PE ratio of 9.02, a price-to-earnings-growth ratio of 0.28 and a beta of 0.47. PTC Therapeutics, Inc. has a 52-week low of $35.95 and a 52-week high of $87.50. The business's fifty day moving average is $71.22 and its 200 day moving average is $58.02.
PTC Therapeutics (NASDAQ:PTCT - Get Free Report) last announced its earnings results on Tuesday, November 4th. The biopharmaceutical company reported $0.20 earnings per share for the quarter, topping analysts' consensus estimates of ($1.19) by $1.39. The business had revenue of $211.01 million for the quarter, compared to analyst estimates of $177.42 million. PTC Therapeutics had a negative return on equity of 194.11% and a net margin of 42.25%.The company's quarterly revenue was up 7.2% compared to the same quarter last year. During the same period in the prior year, the company earned ($1.39) EPS. On average, sell-side analysts forecast that PTC Therapeutics, Inc. will post -4.52 EPS for the current fiscal year.
Analyst Upgrades and Downgrades
Several brokerages have issued reports on PTCT. Bank of America dropped their target price on shares of PTC Therapeutics from $82.00 to $76.00 and set a "buy" rating for the company in a research report on Wednesday, August 20th. Morgan Stanley reduced their target price on PTC Therapeutics from $76.00 to $71.00 and set an "overweight" rating on the stock in a research note on Wednesday, August 20th. TD Cowen lifted their price target on PTC Therapeutics from $50.00 to $63.00 and gave the stock a "hold" rating in a research note on Wednesday, November 5th. The Goldman Sachs Group increased their price objective on PTC Therapeutics from $44.00 to $50.00 and gave the company a "sell" rating in a research report on Wednesday, November 5th. Finally, Cantor Fitzgerald reissued an "overweight" rating and set a $118.00 price objective on shares of PTC Therapeutics in a report on Wednesday, September 3rd. Nine analysts have rated the stock with a Buy rating, seven have issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company has an average rating of "Hold" and an average target price of $76.00.
View Our Latest Stock Report on PTC Therapeutics
Institutional Investors Weigh In On PTC Therapeutics
Several institutional investors have recently added to or reduced their stakes in the company. Wellington Management Group LLP lifted its stake in shares of PTC Therapeutics by 13.2% during the 1st quarter. Wellington Management Group LLP now owns 5,419,172 shares of the biopharmaceutical company's stock worth $276,161,000 after acquiring an additional 632,049 shares during the last quarter. State Street Corp increased its stake in PTC Therapeutics by 22.1% in the second quarter. State Street Corp now owns 2,996,454 shares of the biopharmaceutical company's stock worth $146,347,000 after purchasing an additional 541,558 shares during the period. Geode Capital Management LLC lifted its position in shares of PTC Therapeutics by 3.2% during the second quarter. Geode Capital Management LLC now owns 1,934,593 shares of the biopharmaceutical company's stock worth $94,497,000 after purchasing an additional 60,707 shares during the last quarter. Jefferies Financial Group Inc. bought a new stake in shares of PTC Therapeutics during the third quarter worth $97,252,000. Finally, Driehaus Capital Management LLC boosted its stake in shares of PTC Therapeutics by 45.3% during the first quarter. Driehaus Capital Management LLC now owns 1,512,645 shares of the biopharmaceutical company's stock valued at $77,084,000 after purchasing an additional 471,586 shares during the period.
PTC Therapeutics Company Profile
(
Get Free Report)
PTC Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders in the United States and internationally. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
